Effectiveness of abaloparatide in patients with osteoporosis
Subcutaneous abaloparatide reduces the risk of new vertebral and nonvertebral fractures over 18 months in patients with osteoporosis, according to a study in JAMA.…




*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.